Roche decries biotech's 'bubble'; AbbVie presses into Phase III with uterine fibroid drug;

@FierceBiotech: Adding iridium may offer a new approach to antibiotic resistance. FierceBiotechResearch story | Follow @FierceBiotech

@JohnCFierce: Building its cardio drug portfolio, Amgen bags Dezima in $1.55B deal. News | Follow @JohnCFierce

@DamianFierce: "Ubiquitin" sounds like a McGuffin from a bad sci-fi movie and also it's the target of a new $150M $CELG partnership. Release | Follow @DamianFierce

> Roche ($RHHBY) CEO Severin Schwann reiterated his concerns that biotech is in the midst of a "bubble," saying valuations of small drugmakers have become prohibitively high. News

> AbbVie ($ABBV) and partner Neurocrine Biosciences ($NBIX) are planning to launch a Phase III trial of their uterine fibroid treatment elagolix in early 2016 after tracking a positive effect in Phase IIb. More

> Amid rampant M&A in biopharma, diabetes magnate Novo Nordisk ($NVO) has largely shied away from big deals, part of CEO Lars Sørensen's ethos of focusing on organic growth. Story

Medical Device News

@FierceMedDev: MDxHealth's $8.8M acquisition of NovioGendix is a liquid biopsy play. FierceDiagnostics article | Follow @FierceMedDev

@VarunSaxena2: UPDATED: FDA begs manufacturers to participate in global single audit pilot, says next stage may not be voluntary. ICYMI | Follow @VarunSaxena2

@EmilyWFierce: Germany's ERBA Diagnostics grabs Lumora for molecular Dx tech. FierceDiagnostics story | Follow @EmilyWFierce

> Pentax backs $8M+ round for electrosurgery startup Creo. More

> Illumina, Sloan Kettering partner to develop circulating tumor DNA diagnostics. Article

Pharma News

@FiercePharma: Report: Cancer drug spending fuels large increases in Medicare discount drug program. More | Follow @FiercePharma

@CarlyHFierce: ICYMI: Boehringer's Ofev, chasing a Roche rival, wins backing from NICE. More | Follow @CarlyHFierce

> Will payers make SGLT2 moves on Jardiance CV data? Not just yet. More

> Analysis: New Novartis heart failure med has consumers talking. Item

> Report: Cancer drug spending fuels large increases in Medicare discount drug program. Article

Biotech Research News

> Controversial resveratrol triggers new headlines--this time for Alzheimer's. Story

> Stanford team spotlights a new target for childhood brain tumors. Report

> Adding iridium may offer a new approach to antibiotic resistance. Story

> Caltech IDs an antibody that can thwart HIV. Item

> U.K. investigators say diabetes drug may target pancreatic cancer stem cells. Article

Diagnostics News

> Agilent buys Seahorse Bio for $235M to increase presence in research labs. More

> MDxHealth's $8.8M acquisition of NovioGendix is a liquid biopsy play. News

> Exosome Diagnostics reveals positive data for lung cancer liquid biopsy test. Story

> Foundation Medicine unveils new NGS cancer tool amid sluggish reimbursement. Article

> Pathway Genomics launches liquid biopsy test for early cancer screening. Report

Pharma Marketing News

> GSK settles big media review, chooses incumbents for estimated $900M account. Report

> Gallup charts another big slide for pharma's public image. Story

> Faster track to 'megablockbuster'? Novartis' Entresto already soaring on social media. Article

> Obama taps former Duke researcher to lead FDA. Item

> How much is first-to-market worth? There's a formula for that. More

Suggested Articles

The action will see Kiadis switch its attention to earlier-stage natural killer cell therapies against solid tumors and hematological cancers.

The Weill Family Foundation is stumping up $106 million to create a so-called “Neurohub.”

The takeover centers on TRPML1 agonists designed to treat neurodegenerative disorders by clearing toxic proteins from the brain.